Side-by-side comparison of AI visibility scores, market position, and capabilities
San Francisco AI care platform automating chronic disease patient communication via SMS for health systems; extends care team capacity across oncology, cardiology, and behavioral health.
Memora Health is a San Francisco-based care enablement company that provides health systems with an AI platform to automate patient communication, care navigation, and chronic disease management between clinical visits. The platform uses conversational AI delivered via SMS to check in with patients, answer frequently asked questions, capture symptom reports, and escalate concerning findings to clinical staff — extending care team capacity without adding headcount. Memora targets chronic condition management programs including oncology, cardiovascular care, behavioral health, and pregnancy, where consistent patient monitoring between visits improves outcomes and reduces preventable hospitalizations. The platform integrates with EHR systems and enables care coordinators to manage larger patient panels by automating the routine communication that consumed their time. Founded in 2017, Memora raised over $80M from investors including General Catalyst, Andreessen Horowitz, and Kaiser Permanente Ventures. It competes with Luma Health and Welkin Health in the patient engagement and care management platform market.
Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.